News
In the FIGHT trial of patients with advanced HF, the GLP-1 agonist liraglutide did not improve survival or rates of rehospitalization at 6 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback